Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure: a Multicenter Prospective Observational Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04033224|
Recruitment Status : Not yet recruiting
First Posted : July 26, 2019
Last Update Posted : July 26, 2019
|Condition or disease||Intervention/treatment|
|Critical Illness Acute Kidney Injury Sepsis Systemic Inflammatory Response Syndrome||Device: Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|
Show Detailed Description
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||1000 participants|
|Target Follow-Up Duration:||7 Days|
|Official Title:||Use of Extracorporeal Blood Purification Therapies in Critically Ill Patients With Acute Renal Injury and / or Multiorgan Failure: a Multicenter Prospective Observational Registry|
|Estimated Study Start Date :||September 2019|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2021|
Critically ill patients
In centres that obtained IRB approval for this prospective study, all critically ill patients undergoing EBPTs for support/replacement renal function or immunomodulation will be prospectively observed.
Device: Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)
Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
- Identification of the subpopulation of critically ill patients that most benefits from EBPTs. [ Time Frame: 7 days after EBPT initiation ]This subpopulation will be described using the baseline variables associated with a positive long-term patient's outcome. In particular baseline variables statistically associated through multivariable stepwise analyses with the patient's survival at hospital discharge will be identified and expressed with their Odds ratios, 95%CI and p-value
- Description of the over-time variation of clinical variables during EBPs [ Time Frame: 24 hours after EBPT initiation ]This over-time variation will be expressed, for each variable, as a percentage variation compared with the baseline value (at the EBPT initiation).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04033224
|Contact: Gianluca Villa, MDemail@example.com|